natgillin/translations-raw huggingface dataset:
In the integrated data, 26.5% in the JETREA group compared with 10.1% in the placebo group achieved VMA resolution at Day 28 (p &lt; 0.001).
U integriranim podacima, u 26,5% bolesnika u JETREA skupini u usporedbi s 10,1% u skupini placebo VMA se povukla 28. dana (p &lt; 0,001).
In the ITT population of an open label dose response study, DPM-CF-202, the mean (SD) percent change in FEV1 for the 400 mg dose was 8.75 (SD: 12.4) and -1.569 (SD: 9.0) for 40 mg dose (p &lt; 0.0001).
U otvorenom ispitivanju reakcije na dozu u ITT populacije, DPM-CF-202, srednja (SD) postotna promjena vrijednosti FEV1 za dozu od 400 mg iznosila je 8,75 (SD: 12,4) te -1,569 (SD: 9,0) za dozu od 40 mg (p &lt; 0,0001).
In the joint analysis of the NSABP B-31 and NCCTG N9831 studies, EBC was limited to women with operable breast cancer at high risk, defined as HER2-positive and axillary lymph node positive or HER2 positive and lymph node negative with high risk features (tumor size &gt; 1 cm and ER negative or tumor size &gt; 2 cm, regardless of hormonal status).
U skupnoj analizi ispitivanja NSABP B-31 i NCCTG N9831, rani rak dojke je bio ograničen isključivo na žene s operabilnim rakom dojke visokog rizika, definiranim kao HER2 pozitivan s pozitivnim aksilarnim limfnim čvorovima ili HER2 pozitivan s negativnim aksilarnim limfnim čvorovima sa značajkama visokog rizika (veličina tumora &gt; 1 cm i ER negativan ili veličina tumora &gt; 2 cm, bez obzira na hormonski status).
In the large phase 3 clinical trial, the mean estimated exposure (AUC) of the active metabolite was 19% higher in very elderly patients (≥ 75 years of age) compared to subjects &lt; 75 years of age.
U velikom kliničkom ispitivanju, u fazi III, prosječna procijenjena izloženost (AUC) aktivnom metabolitu bila je 19% veća u vrlo starih bolesnika (≥ 75 godina) u usporedbi s ispitanicima mlađima od 75 godina.
In the majority of instances, such complications began immediately or soon ( &lt; 24 hours) after delivery.
U većini slučajeva takve su komplikacije počele odmah ili uskoro ( &lt; 24 sata) nakon poroda.
In the majority of patients fluticasone furoate is not quantifiable ( &lt; 10 pg/ml) following intranasal dosing of 110 micrograms once daily.
Kod većine bolesnika flutikazonfuroat nije mjerljiv ( &lt; 10 pg/ml) nakon intranazalnog doziranja od 110 mikrograma jednom na dan.
In the meta-analysis, the overall mean difference to placebo across the studies was statistically significant: -2.3 points (p = 0.007), -3.6 points (p &lt; 0.001), and -4.6 points (p &lt; 0.001) for the 5, 10, and 20 mg/day doses, respectively; the 15 mg/day dose did not separate from placebo in the meta-analysis, but the mean difference to placebo was -2.6 points.
U meta analizama, ukupna srednja razlika od placeba kroz ispitivanja je bila statistički značajna: -2,3 boda (p=0,007), -3,6 bodova (p &lt; 0,001 i -4,6 bodova (p &lt; 0,001) za doze od 5, 10 odnosno 20 mg dnevno; doza od 15 mg dnevno se nije udaljila od placeba u meta analizi, ali je razlika od placeba bila -2,6 bodova.
In the meta-analysis, the overall mean difference to placebo across the studies was statistically significant: -2.3 points (p = 0.007), -3.6 points (p &lt; 0.001), and -4.6 points (p &lt; 0.001) for the 5, 10, and 20 mg/day doses, respectively; the 15mg/day dose did not separate from placebo in the meta-analysis, but the mean difference to placebo was -2.6 points.
U meta analizama, ukupna srednja razlika od placeba kroz ispitivanja je bila statistički značajna: -2,3 boda (p=0,007), -3,6 bodova (p &lt; 0,001 i -4,6 bodova (p &lt; 0,001) za doze od 5, 10 odnosno 20 mg dnevno; doza od 15 mg dnevno se nije udaljila od placeba u meta analizi, ali je razlika od placeba bila -2,6 bodova.
In the overall patient population of the study MF 4411, no reduction was observed for non-vertebral fractures, however daily ibandronic acid appeared to be effective in a high-risk subpopulation (femoral neck BMD T-score &lt; -3.0), where a non-vertebral fracture risk reduction of 69 % was observed.
U ukupnoj populaciji bolesnika ispitivanja MF4411 nije uočeno smanjenje broja nevertebralnih prijeloma, no čini se da je dnevna doza ibandronata djelotvorna u visokorizičnoj populacijskoj podskupini (T-vrijednost BMD za vrat bedrene kosti &lt; -3,0), u kojoj je primijećeno smanjenje rizika od nevertebralnih prijeloma za 69%.
In the overall patient population of the study MF4411, no reduction was observed for non-vertebral fractures, however daily ibandronic acid appeared to be effective in a high-risk subpopulation (femoral neck BMD T-score &lt; -3.0), where a non-vertebral fracture risk reduction of 69 % was observed.
U ukupnoj populaciji bolesnika u ispitivanju MF4411 nije uočeno smanjenje broja ne-vertebralnih prijeloma , no čini se da je dnevna doza ibandronata djelotvorna u visokorizičnoj populacijskoj podskupini (T-vrijednost BMD za vrat bedrene kosti &lt; -3,0), u kojoj je primijećeno smanjenje rizika od ne-vertebralnih prijeloma za 69%.
In the overall patient population of the study MF4411, no reduction was observed for non-vertebral fractures, however daily ibandronic acid appeared to be effective in a high-risk subpopulation (femoral neck BMD T-score &lt; -3.0), where a non-vertebral fracture risk reduction of 69% was observed.
U ukupnoj populaciji bolesnika ispitivanja MF4411 nije uočeno smanjenje broja nevertebralnih prijeloma, no čini se da je dnevna doza ibandronata djelotvorna u visokorizičnoj populacijskoj podskupini (T-vrijednost BMD za vrat bedrene kosti &lt; -3,0), u kojoj je primijećeno smanjenje rizika od nevertebralnih prijeloma za 69%.
In the overall patient population of the study MF4411, no reduction was observed for non-vertebral fractures, however daily ibandronic acid appeared to be effective in a high-risk subpopulation (femoral neck BMD T-score &lt; -3.0), where a non-vertebral fracture risk reduction of 69% was observed.
U ukupnoj populaciji bolesnika u ispitivanju MF4411 nije uočeno smanjenje broja ne-vertebralnih prijeloma , no čini se da je dnevna doza ibandronata djelotvorna u visokorizičnoj populacijskoj podskupini (T-vrijednost BMD za vrat bedrene kosti &lt; -3,0), u kojoj je primijećeno smanjenje rizika od ne-vertebralnih prijeloma za 69%.
In the overall SJIA program, high ALT and/or AST &gt; 3 x upper limit of normal (ULN) were reported in 19 patients (9.5%).
U cjelokupnom programu za SJIA-u zabilježene su visoke razine ALT-a i/ili AST-a &gt; 3 x gornja granica normale (GGN) u 19 bolesnika (9,5%).
In the overall SJIA program, transient decreases in platelet counts ( &lt; LLN) were observed in 19 patients (9.5%).
U cjelokupnom programu za SJIA-u zabilježena su prolazna smanjenja broja trombocita ( &lt; DGN) u 19 bolesnika (9,5%).
In the paediatric bipolar population (10-17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females ( &lt; 3 ng/ml) and males ( &lt; 2 ng/ml) was 28.0 % and 53.3 %, respectively.
U pedijatrijskoj populaciji s bipolarnim poremećajem (10-17 godina), koja je lijeku bila izložena tijekom najviše 30 tjedana, incidencija niskih vrijednosti prolaktina u serumu iznosila je 28,0 % u djevojčica ( &lt; 3 ng/ml) i 53,3 % u dječaka ( &lt; 2 ng/ml).
In the paediatric bipolar population (10-17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females ( &lt; 3 ng/ml) and males ( &lt; 2 ng/ml) was 28.0% and 53.3%, respectively.
U pedijatrijskoj populaciji s bipolarnim poremećajem (10-17 godina), koja je lijeku bila izložena tijekom najviše 30 tjedana, incidencija niskih vrijednosti prolaktina u serumu iznosila je 28,0 % u djevojčica ( &lt; 3 ng/ml) i 53,3 % u dječaka ( &lt; 2 ng/ml).
In the patients aged &lt; 20 years the increase from baseline percent predicted FEV1 was larger: 11.3% for TOBI Podhaler and 6.9% for the nebuliser solution after 3 cycles.
U bolesnika u dobi od &lt; 20 godina, povećanje od početne vrijednosti postotka predviđenog FEV1 bilo je veće: 11,3% za TOBI Podhaler i 6,9% za otopinu za nebulizator nakon 3 ciklusa.
In the pharmacokinetic studies conducted in patients following a single dose of Numient, systemic exposure to levodopa generally increased with increasing age with AUC values being, on average, approximately 15% higher in elderly (≥65 years) than younger subjects ( &lt; 65 years).
U farmakokinetičkim ispitivanjima provedenim u bolesnika nakon pojedinačne doze Numienta, sistemska izloženost levodopi općenito je rasla s porastom godina s vrijednostima AUC u prosjeku, otprilike 15 % višim u starijih (≥ 65 godina) nego u mlađih ispitanika ( &lt; 65 godina).
In the Phase 1/2 clinical study in patients with previously treated Ph+ leukaemias, QTcF interval changes &gt; 60 ms from baseline were observed 6 (1.1%) of 562 patients.
U kliničkom ispitivanju u fazi 1/2 u bolesnika s prethodno liječenim Ph+ leukemijama promjene QTcF intervala &gt; 60 ms u odnosu na početne vrijednosti zapažene su u 6 (1,1%) od 562 bolesnika.
In the phase 3 clinical trial these patients were at greater risk of bleeding, including fatal bleeding, compared to patients &lt; 75 years of age.
U faze III kliničkog ispitivanja ti su bolesnici bili izloženi većem riziku od krvarenja, uključujući i ona sa smrtnim ishodom, u usporedbi s bolesnicima mlađima od 75 godina.
In the phase 3 clinical trial these patients were at greater risk of bleeding, including fatal bleeding, compared to patients &lt; 75 years of age.
U fazi III kliničkog ispitivanja ti su bolesnici bili izloženi većem riziku od krvarenja, uključujući i ona sa smrtnim ishodom, u usporedbi s bolesnicima mlađima od 75 godina.
In the Phase 3 studies, none of the patients with HCV RNA &gt; 1,000 IU/ml at either week 4 or week 12 achieved SVR with continued peginterferon alfa and ribavirin treatment.
U fazi III ispitivanja niti jedan od bolesnika s HCV RNK &gt; 1000 IU/ml u 4. ili 12. tjednu nije postigao SVR uz nastavak liječenja peginterferonom alfa i ribavirinom.
In the Phase 3 trial, 3 of 4 patients with ALT elevations &gt; 5x ULN reported alcohol consumption beyond the limits recommended in the protocol.
U ispitivanju faze 3, u 3 od 4 bolesnika s povišenjem vrijednosti ALT &gt; 5 x GGN zabilježena je konzumacija alkohola iznad ograničenja preporučenog protokolom.
In the Phase III study in patients with newly diagnosed chronic phase CML, one patient ( &lt; 1%) of the SPRYCEL-treated patients had a QTcF &gt; 500 msec after a minimum of 12 months follow-up (see section 4.4).
U ispitivanju faze III u bolesnika s novodijagnosticiranom KML u kroničnoj fazi, nakon najmanje 12 mjeseci praćenja (vidjeti dio 4.4), jedan bolesnik ( &lt; 1%) u skupini liječenoj lijekom SPRYCEL imao je QTcF &gt; 500 msek.
In the Phase III study MEK116513 four patients (1%) treated with trametinib in combination with dabrafenib had a QTcB Grade 3 increase ( &gt; 500 msec).
U ispitivanju faze III MEK116513 četiri bolesnika (1%) liječenih trametinibom u kombinaciji s dabrafenibom imalo je povećanje QTcB 3. stupnja ( &gt; 500 ms).
In the pitolisant group, ESS decreased significantly between baseline and the end of treatment compared to placebo with an observed mean change of -1.9 ± 4.3 and -5.4 ± 4.3 (mean ± sd) for placebo and pitolisant respectively, (p &lt; 0.0001) (Figure 3).
U skupini koja je primala pitolizant, ESS se značajno smanjio od početka do kraja liječenja u odnosu na skupinu koja je primala placebo, uz opaženu srednju vrijednost promjene od -1,9 ± 4,3 za placebo i -5,4 ± 4,3 (srednja vrijednost ± SD) za pitolizant (p &lt; 0,0001) (slika 3).
In the pivotal clinical study (study 1), the primary endpoint was the average sum of differences in pain intensity scores from dosing to 60 minutes, inclusive (SPID60), which was statistically significant compared to placebo (p &lt; 0.0001).
U pivotalnom kliničkom ispitivanju (ispitivanje 1) primarni ishod bio je prosječni zbroj razlika u rezultatima intenziteta boli od doziranja do 60 minuta uključivo (SPID60) koja je bili statistički značajna u usporedbi s placebom (p &lt; 0,0001).
In the pivotal non-dialysis study 204 CKD ND patients treated with Fexeric had a significant increase in serum TSAT, ferritin and haemoglobin levels compared to the placebo group after 12 weeks of treatment (p &lt; 0.001 for treatment difference for each parameter) (Table 4).
U pivotalnom ispitivanju 204 na bolesnicima koji nisu na dijalizi, bolesnici s KBB ND liječeni Fexericom imali su značajno povećanje razina TSAT-a, feritina i hemoglobina u serumu u usporedbi sa skupinom liječenom placebom nakon 12 tjedana liječenja (p &lt; 0,001 za razliku u liječenju za svaki parametar) (Tablica 4).
In the pivotal study in iNHL, a small subset of 8% (15 out of 194) of patients treated with Gazyvaro plus bendamustine, had moderate renal impairment (CrCL &lt; 50 mL/min).
U ključnom ispitivanju kod iNHL-a, mala podskupina od 8% (15/194) bolesnika liječenih lijekom Gazyvaro plus bendamustinom imala je umjereno oštećenje funkcije bubrega (CrCl &lt; 50 ml/min).
In the pivotal study, Preotact increased BMD in the lumbar spine after 18 months treatment by 6.5 compared with -0.3 for placebo (p0.001).
Prema pivotalnom ispitivanju, Preotact povećava BMD u lumbalnoj kralježnici za 6,5% nakon 18 mjeseci liječenja u usporedbi sa -0,3% za placebo (p &lt; 0,001).
In the pivotal trial BO22227, there were more than twice as many patients reporting all grade hypertension with the Herceptin subcutaneous formulation (4.7 % versus 9.8 % in the intravenous and subcutaneous formulations respectively), with a greater proportion of patients with severe events (NCI CTCAE grade ≥3) &lt; 1 % versus 2.0 % the intravenous and subcutaneous formulations respectively.
U pivotalnom ispitivanju BO22227 hipertenziju je prijavio više nego dvostruko veći broj bolesnica koje su primale Herceptin u supkutanoj formulaciji (4,7% uz intravensku formulaciju naspram 9,8% uz supkutanu formulaciju), a pritom je i veći udio bolesnica prijavio teške događaje (NCI CTCAE stupnja ≥ 3), &lt; 1% uz intravensku formulaciju naspram 2,0% uz supkutanu formulaciju.
In the placebo+MTX group, 49.7% of patients experienced no radiographic progression (change in mTSS ≤0.5) at Week 52 compared to 70.3% in the Cimzia+MTX group (p &lt; 0.001).
U 49,7% bolesnika koji su primali placebo+MTX nije zabilježena radiografska progresija (promjena u mTSS ≤0,5) u 52. tjednu u usporedbi sa 70,3% bolesnika koji su primali Cimziju+MTX (p &lt; 0,001).
In the placebo-controlled phase, Extavia delayed the progression from the first clinical event to clinically definite multiple sclerosis (CDMS) in a statistically significant and clinically meaningful manner, corresponding to a risk reduction of 47% (Hazard Ratio = 0.53, 95% confidence interval (0.39, 0.73), p &lt; 0.0001).
U placebom kontroliranoj fazi, Extavija je odgodila progresiju od prvog kliničkog događaja do klinički definitivne multiple skleroze (KDMS) na statistički i klinički značajan način, što odgovara smanjenju rizika za 47% (omjer hazarda = 0,53, interval pouzdanosti 95% (0,39, 0,73), p &lt; 0,0001).
In the placebo-controlled studies, most patients ( &gt; 98%) had normal lymphocyte values prior to initiating treatment.
Većina je bolesnika u placebom kontroliranim ispitivanjima ( &gt; 98%) imala normalne vrijednosti limfocita prije početka liječenja.
In the pooled adolescent schizophrenia population (13-17 years) with exposure up to 2 years, incidence of low serum prolactin levels in females ( &lt; 3 ng/ml) and males ( &lt; 2 ng/ml) was 29.5% and 48.3%, respectively.
U cjelokupno ispitanoj populaciji adolescenata sa shizofrenijom (u dobi od 13 do 17 godina) koji su primali lijek u trajanju do 2 godine, incidencija niske razine prolaktina u serumu u djevojaka ( &lt; 3 ng/ml) bila je 29,5 %, a u mladića ( &lt; 2 ng/ml) 48,3 %.
In the pooled analysis from NV-02B-007 (GLOBE) and NV-02B-015, by 104 weeks of treatment grade 3 or4 CK elevations ( &gt; 7x ULN) occurred in 12.6% of telbivudine-treated patients (n = 847) and 4.0% of lamivudine-treated patients (n = 846).
U udruženoj analizi ispitivanja NV-02B-007 (GLOBE) i NV-02B-015, do 104. tjedna liječenja, porast kreatin kinaze stupnja 3 ili 4 ( &gt; 7x GGN) pojavio se u 12,6% bolesnika liječenih telbivudinom te u 4,0% bolesnika liječenih lamivudinom.
In the Pooled Phase 1 database, AEs considered common (≥ 1/100 to &lt; 1/10) or very common (≥ 1/10) and more frequent among subjects treated with sugammadex than in the placebo group, include dysgeusia (10.1%), headache (6.7%), nausea (5.6%), urticaria (1.7%), pruritus (1.7%), dizziness (1.6%), vomiting (1.2%) and abdominal pain (1.0%).
U objedinjenoj bazi podataka iz faze 1, nuspojave koje su se smatrale čestima (≥ 1/100 i &lt; 1/10) ili vrlo čestima (≥ 1/10) i koje su bile učestalije u ispitanika liječenih sugamadeksom nego placebom uključivale su disgeuziju (10,1%), glavobolju (6,7%), mučninu (5,6%), urtikariju (1,7%), svrbež (1,7%), omaglicu (1,6%), povraćanje (1,2 %) i bol u abdomenu (1,0%).
In the pooled trials, the incidence of low serum prolactin levels in females ( &lt; 3 ng/ml) and males ( &lt; 2 ng/ml) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively.
U objedinjenim je ispitivanjima incidencija niske razine prolaktina u serumu u djevojčica ( &lt; 3 ng/ml) liječenih aripiprazolom iznosila 27/46 (58,7 %), a u dječaka ( &lt; 2 ng/ml) 258/298 (86,6 %).
In the pooled trials, the incidence of low serum prolactin levels in females ( &lt; 3 ng/ml) and males ( &lt; 2 ng/ml) in aripiprazole-treated patients was 27/46 (58.7%) and 258/298 (86.6%), respectively.
U objedinjenim je ispitivanjima incidencija niske razine prolaktina u serumu u djevojčica ( &lt; 3 ng/ml) liječenih aripiprazolom iznosila 27/46 (58,7 %), a u dječaka ( &lt; 2 ng/ml) 258/298 (86,6 %).
In the population pharmacokinetic analysis using data from clinical trials in patients with metastatic melanoma, mild and moderate renal impairment did not influence the apparent clearance of vemurafenib (creatinine clearance &gt; 40 ml/min).
U populacijskoj farmakokinetičkoj analizi u kojoj su korišteni podaci iz kliničkih ispitivanja u bolesnika s metastatskim melanomom, blago i umjereno oštećenje bubrežne funkcije nije utjecalo na prividni klirens vemurafeniba (klirens kreatinina &gt; 40 ml/min).
In the pre-liver transplantation and post-liver transplantation cohorts 77 of 109 (71 %) patients and 64 of 159 (40 %) patients, respectively, achieved undetectable HBV DNA levels at week 48 ( &lt; 1,000 copies/ml Roche Amplicor Monitor PCR assay).
Razina HBV DNK postala je nemjerljiva u 48. tjednu ( &lt; 1000 kopija/ml prema PCR testu Roche Amplicor Monitor) u 77 od 109 (71%) pacijenata u kohorti prije transplantacije jetre i 64 od 159 (40%) pacijenata u kohorti nakon transplantacije jetre.
In the primary 48 weeks analysis, the proportion of patients with virologic suppression in the dolutegravir + ABC/3TC arm , was superior to the EFV/TDF/FTC arm, p=0.003, the same treatment difference was observed in subjects defined by baseline HIV RNA level ( &lt; or &gt; 100,000 copies/mL).
U primarnoj analizi 48 tjedana liječenja, udio bolesnika s virološkom supresijom u skupini liječenoj kombinacijom dolutegravir + ABC/3TC bio je superioran u odnosu na skupinu koja je primala EFV/TDF/FTC (p=0,003), a ista razlika između liječenja primijećena je i među ispitanicima grupiranima prema početnoj razini HIV RNK ( &lt; ili &gt; 100 000 kopija/ml).
In the re-treatment arm, 4% (8/219) of patients experienced a serious infusion reaction versus &lt; 1% (1/222) on maintenance therapy.
U skupini u kojoj je ponovljena uvodna shema liječenja ozbiljnu reakciju na infuziju razvilo je 4% (8/219) bolesnika u odnosu na &lt; 1% bolesnika (1/222) koji su primali terapiju održavanja.
In the re-treatment arm, 4% (8/219) of patients experienced a serious infusion reaction versus &lt; 1% (1/222) on maintenance therapy.
U skupini u kojoj je ponovljena uvodna shema liječenja ozbiljnu reakciju na infuziju razvilo je 4% (8/219) bolesnika u odnosu na
In the SAILING study, virologic suppression (HIV-1 RNA &lt; 50 copies/mL) in the Tivicay arm (71%) was statistically superior to the raltegravir arm (64%), at Week 48 (p=0.03).
U ispitivanju SAILING je virološka supresija (HIV-1 RNK &lt; 50 kopija/m) u skupini koja je primala Tivicay (71%) nakon 48 tjedana bila statistički superiorna u odnosu na skupinu koja je primala raltegravir (64%) (p=0,03).
In the second double-blind 28- week treatment period the difference in rates between treatment groups represented a 63% (rate ratio 0.37, p &lt; 0.001) decrease relative to placebo for omalizumab patients.
U drugom dvostruko slijepom 28-tjednom razdoblju liječenja razlika u stopama između terapijskih skupina bila je 63%-tno smanjenje (omjer stopa 0,37, p &lt; 0,001) kod bolesnika liječenih omalizumabom u odnosu na placebo.
In the second pivotal study (study 2), the primary endpoint was SPID30, which was also statistically significant compared to placebo (p &lt; 0.0001).
U drugom pivotalnom kliničkom ispitivanju (ispitivanje 2) primarni ishod bila je vrijednost SPID30 koja je također bila statistički značajna u usporedbi s placebom (p &lt; 0,0001).
In the second study in 48 patients with mild to moderate asthma who had previously been shown to have bronchoconstrictive reactions to adenosine monophosphate, the rate of FEV1 reduction &gt; 15% from baseline was the same (4%) following both Rapiscan and placebo dosing.
U drugom ispitivanju na 48 bolesnika s blagom do umjerenom astmom koji su ranije reagirali bronhokonstrikcijom na adenozinmonofosfat, stopa smanjenja FEV1 &gt; 15% od početnih vrijednosti bila je jednaka (4%) nakon primjene doze i Rapiscana i placeba.
In the second study, LAVENTAIR 55/22 micrograms showed improvements compared with placebo in change from baseline in lung volume measures at trough and at 3 hours post dose at Week 12 (inspiratory capacity: 198 ml and 238 ml respectively, residual volume: -295 ml and -351 ml respectively and functional residual capacity: -238 ml and -302 ml respectively); all p &lt; 0.001).
U drugom je ispitivanju LAVENTAIR od 55/22 mikrograma u 12. tjednu doveo do poboljšanja u usporedbi s placebom s obzirom na promjenu plućnog volumena izmjerenog na kraju intervala doziranja i 3 sata nakon primjene doze u odnosu na početnu vrijednost (udisajni kapacitet: 198 ml odnosno 238 ml, rezidualni volumen: -295 ml do -351 ml i funkcionalni rezidualni kapacitet: -238 ml do -302 ml; p &lt; 0,001* za sve).
In the SIRTURO group, no or only minor differences in time to culture conversion and culture conversion rates were observed between patients with pre-XDR-TB and patients with MDRH &amp; R-TB.
U SIRTURO skupini, razlike ili nisu primijećene ili su primijećene samo manje razlike u vremenu do konverzije kulture i u stopama konverzije kulture sputuma između bolesnika s pre-XDR-TB tuberkulozom i bolesnika s MDRH &amp; R-TB.
In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value &lt; 0.0001] (see Table 9).
U ispitivanju je apiksaban bio statistički uspješniji od enoksaparina/varfarina u primarnom sigurnosnom ishodu [Relativni rizik 0,31, 95%-tni interval pouzdanosti (0,17, 0,55), P-vrijednost &lt; 0,0001] (vidjeti Tablicu 11).
In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value &lt; 0.0001] (see Table 11).
U ispitivanju je apiksaban bio statistički uspješniji od enoksaparina/varfarina u primarnom sigurnosnom ishodu [Relativni rizik 0,31, 95%-tni interval pouzdanosti (0,17, 0,55), P-vrijednost &lt; 0,0001] (vidjeti Tablicu 11).
In the sub-group of patients indicated for treatment of rapidly evolving relapsing remitting MS (patients with 2 or more relapses and 1 or more Gd+ lesion), the annualised relapse rate was 0.282 in the TYSABRI treated group (n = 148) and 1.455 in the placebo group (n = 61) (p &lt; 0.001).
U podskupini bolesnika u kojih je postojala indikacija za liječenje brzonapredujuće relapsnoremitentne multiple skleroze (bolesnici s dva ili više relapsa i jednom ili više lezija utvrđenih gadolinijem) godišnja stopa relapsa iznosila je 0,282 za skupinu koja je primala TYSABRI (n = 148) i 1,455 za skupinu koja je primala placebo (n = 61) (p &lt; 0,001).